Moderna said on Wednesday it would stop developing its experimental vaccine to prevent cytomegalovirus, a virus that can ...

I agree to the Terms of Use , Privacy Notice and Cookie Notice. I would like to receive updates and special offers from Dow ...

The young UK resident was born with a condition called spina bifida and had a tumor in his spine Tommy was born with a birth ...

(NASDAQ:MRNA) today announced topline results from a Phase 3 pivotal trial evaluating the efficacy of mRNA-1647, the ...

As federal workers face mass layoffs and a government shutdown, Dr. Frances Oldham Kelsey's story is a reminder of what ...

A shot analysts projected as a multibillion-dollar seller produced results “well below” the company’s expectations, ...

Stress on considering public opinion before taking up projectsPoint out that the TDP leaders failed to pay heed to the pleas ...

The vaccine, known as mRNA-1647, showed disappointing efficacy against primary CMV infection in healthy women, ranging from ...

Moderna said its cytomegalovirus (CMV) vaccine didn't meet the primary efficacy endpoint in a Phase 3 trial, and it is discontinuing the clinical development program.

As parents, find out what are the two categories of heart problems and the reasons behind them, so your children's health can be safeguarded.

Kenvue, the maker of Tylenol, opposes proposed changes to the product's safety label regarding potential links to autism and ...

The Ministry of Health in collaboration with partners will embark on a nationwide Measles Rubella Vaccination Campaign starting 23rd to 28th October 2028.